Tom Jefferson competing interests statement 7 October 2026
TJ was in receipt of a Cochrane Methods Innovations Fund grant to develop guidance on the use of regulatory data in Cochrane reviews (2015-018).
In 2014–2016, TJ was a member of three advisory boards for Boehringer Ingelheim. TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine.
TJ is occasionally interviewed by market research companies about phase I or II pharmaceutical products for which he receives fees (current).
TJ was a member of three advisory boards for Boehringer Ingelheim (2014-16)
TJ was a member of an independent data monitoring committee for a Sanofi Pasteur clinical trial on an influenza vaccine (2015-2017).
TJ is a relator in a False Claims Act lawsuit on behalf of the United States that involves sales of Tamiflu for pandemic stockpiling. If resolved in the United States’ favor, he would be entitled to a percentage of the recovery.
TJ was co-holder of a Laura and John Arnold Foundation grant for development of a RIAT support centre (2017-2020) and Jean Monnet Network Grant, 2017-2020 for The Jean Monnet Health Law and Policy Network. TJ was an unpaid collaborator to the project Beyond Transparency in Pharmaceutical Research and Regulation led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).
TJ consulted for Illumina LLC on next generation gene sequencing (2019-2020).
TJ was the consultant scientific coordinator for the HTA Medical Technology programme of the Agenzia per i Serivizi Sanitari Nazionali (AGENAS) of the Italian MoH (2007-2019).
TJ is Director Medical Affairs for BC Solutions, a market access company for medical devices in Europe.
TJ was funded by NIHR UK and the World Health Organization (WHO) to update Cochrane review A122, “Physical Interventions to interrupt the spread of respiratory viruses.” The 2023 update was funded by NIHR.
Since 2020, TJ receives fees for articles published by The Spectator and other media outlets.
TJ was part of a review group carrying out “Living rapid literature review on the modes of transmission of SARS-CoV-2 (WHO Registration 2020/1077093-0)”. He is a member of the WHO COVID-19 Infection Prevention and Control Research Working Group.
TJ was funded to co-author rapid reviews on the impact of Covid restrictions by Collateral Global Organisation (2021-22).
TJ was funded by Oxford University to carry out a living review on the transmission epidemiology of COVID-19 and provide consultancy services to the University.
TJ was a consultant to Clarivate Epidemiology LLC (2021-22).
TJ receives revenues from https://trusttheevidence.substack.com
TJ carried out medico-legal work on the following topics: influenza, pertussis and human papilloma virus (HPV) for various legal firms.
TJ carried out a review on dermal replacement therapy for Integra LifeSciences.
TJ was a consultant to Teva Branded Pharmaceutical Products LLC.